Secondary Postpartum Hemorrhage

NCT03840889 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2019-02-15

No results posted yet for this study

Summary

Postpartum hemorrhage (PPH) remains one of the leading causes of maternal mortality and morbidity worldwide, including in France, where it accounts for approximately 20% of maternal mortality. Although numerous studies have examined immediate PPH, very few have explored secondary (also called late) PPH. Moreover, there are no guidelines in France for the management of secondary PPH. Its frequency appears to vary from 0.2% to 3.0% of deliveries. It is, however, difficult to estimate because only severe secondary PPH will lead to hospitalization and the rare publications concern single-center studies. The cause of these secondary hemorrhages is often unknown, due to the lack of routine uterine aspiration. Nonetheless, this aspiration is not always medically justified. The principal objective of this study is thus to establish the incidence of severe late PPH in the general population.

Conditions

  • Postpartum Hemorrhage
  • Maternal Morbidity
  • Retained Placenta
  • Postpartum Endometritis
  • Delivery

Interventions

OTHER

Data collection

he different modes of active data collection: * Data collection by telephone * Data collection by mail * Collection from discharge database summaries (PMSI)

Sponsors & Collaborators

  • CRRF La Châtaigneraie

    collaborator OTHER
  • CH de Moulins

    collaborator UNKNOWN
  • CH de Montluçon

    collaborator UNKNOWN
  • Jacques Lacarin Hospital Center

    collaborator OTHER
  • CH de Thiers

    collaborator UNKNOWN
  • CH d'Issoire

    collaborator UNKNOWN
  • CH d'Aurillac

    collaborator UNKNOWN
  • CH du Puy-en-Velay

    collaborator UNKNOWN
  • CH de Saint-Flour

    collaborator UNKNOWN
  • AUDIPOG

    collaborator UNKNOWN
  • Université d'Auvergne

    collaborator OTHER
  • University Hospital, Clermont-Ferrand

    lead OTHER

Principal Investigators

  • Françoise VENDITELLI · University Hospital, Clermont-Ferrand

Eligibility

Min Age
12 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2021-12-31
Completion
2022-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03840889 on ClinicalTrials.gov